Vitamin D for treatment and prevention of infectious diseases: A systematic review of randomized controlled trials

Endocrine Practice

Volumn 15, Issue 5, 2009, Pages 438-449

  Yamshchikov, Alexandra V ^a   Desai, Nirali S ^a   Blumberg, Henry M ^a   Ziegler, Thomas R ^a   Tangpricha, Vin ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL; INFLUENZA VACCINE; PARICALCITOL; PLACEBO; PRAZIQUANTEL; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; IMMUNE RESPONSE; INFLUENZA; MEDLINE; META ANALYSIS; METHODOLOGY; SAMPLE SIZE; SCHISTOSOMIASIS HAEMATOBIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRAL UPPER RESPIRATORY TRACT INFECTION; VITAMIN SUPPLEMENTATION; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; VIROLOGY; VITAMIN D DEFICIENCY;

COMMUNICABLE DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 70449707918     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09101.ORR     Document Type: Article

References (54)

1. Khajavi A, Amirhakimi GH. The rachitic lung: pulmonary findings in 30 infants and children with malnutritional rickets. Clin Pediatr (Phila). 1977;16:36-38.
2. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol. 2007;103:793-798.
3. Danai PA, Sinha S, Moss M, Haber MJ, Martin GS. Seasonal variation in the epidemiology of sepsis. Crit Care Med. 2007;35:410-415.
4. Grant WB. Variations in vitamin D production could possibly explain the seasonality of childhood respiratory infections in Hawaii. Pediatr Infect Dis J. 2008;27:853.
5. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134:1129-1140.
6. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57:1308-1310.
7. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206:1188-1190.
8. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136-1142.
9. Wactawski-Wende J, Kotchen JM, Anderson GL, et al (Women's Health Initiative Investigators). Calcium plus vitamin D supplementation and the risk of colorectal cancer [published correction appears in N Engl J Med. 2006;354:1102]. N Engl J Med. 2006;354:684-696.
10. Flanagan JN, Young MV, Persons KS, et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006;26:2567-2572.
11. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770-1773.
12. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology. 1986;57:159-163.
13. Crowle AJ, Ross EJ, May MH. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun. 1987;55:2945-2950.
14. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect. 2002;4:361-372.
15. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression [published correction appears in J Immunol. 2004;173:following 6489]. J Immun. 2004;173:2909-2912.
16. Wehkamp J, Schauber J, Stange EF. Defensins and cathelicidins in gastrointestinal infections. Curr Opin Gastroenterol. 2007;23:32-38.
17. Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem. 2001;276:35482-35493.
18. Tachi Y, Shimpuku H, Nosaka Y, et al. Vitamin D receptor gene polymorphism is associated with chronic periodontitis. Life Sci. 2003;73:3313-3321.
19. Malik MH, Jury F, Bayat A, Ollier WE, Kay PR. Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Ann Rheum Dis. 2007;66:1116-1120.
20. Horgan J. Space invaders: Extra! Extra! Flu linked to sunspots! Sci Am. 1990;262:26, 30.
21. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol. 2004;160:492-502.
22. Kobasa D, Takada A, Shinya K, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004;431:703-707.
23. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002;360:1831-1837.
24. Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. Mol Aspects Med. 2008;29:369-375.
25. Gropp R, Frye M, Wagner TO, Bargon J. Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther. 1999;10:957-964.
26. Beisswenger C, Bals R. Antimicrobial peptides in lung inflammation. Chem Immunol Allergy. 2005;86:55-71.
27. Rodríguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25:9-14.
28. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-1382.
29. Connor RI, Rigby WF. 1 alpha,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1. Biochem Biophys Res Commun. 1991;176:852-859.
30. Kizaki M, Ikeda Y, Simon KJ, Nanjo M, Koeffler HP. Effect of 1,25-dihydroxyvitamin D3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages. Leukemia. 1993;7:1525-1530.
31. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5:410-415.
32. Díaz A, Allen JE. Mapping immune response profiles: the emerging scenario from helminth immunology. Eur J Immunol. 2007;37:3319-3326.
33. Romani L. Cell mediated immunity to fungi: a reassessment. Med Mycol. 2008;46:515-529.
34. Actor JK, Olsen M, Jagannath C, Hunter RL. Relationship of survival, organism containment, and granuloma formation in acute murine tuberculosis. J Interferon Cytokine Res. 1999;19:1183-1193.
35. Wejse C. Vitamin D as supplementary treatment for tuberculosis - a double-blind randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009;179:843-850.
36. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007;176:208-213.
37. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones. 2006;38:3-5.
38. Morcos MM, Gabr AA, Samuel S, et al. Vitamin D administration to tuberculous children and its value. Boll Chim Farm. 1998;137:157-164.
39. Kawaura A. Inhibitory effect of long term 1alphahydroxyvitamin D3 administration on Helicobacter pylori infection. J Clin Biochem Nutr. 2006;38:103-106.
40. Moe SM, Zekonis M, Harezlak J, et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis. 2001;38:792-802.
41. Rehman PK. Sub-clinical rickets and recurrent infection. J Trop Pediatr. 1994;40:58.
42. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D [with author reply]. Epidemiol Infect. 2007;135:1095-1098.
43. Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent infections: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2007;36:574-577.
44. Kriesel JD, Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine. 1999;17:1883-1888.
45. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents [published correction appears in Pediatrics. 2009;123:1437]. Pediatrics. 2009;123:e121-e126.
46. Snyman JR, de Sommers K, Steinmann MA, Lizamore DJ. Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis. Eur J Clin Pharmacol. 1997;52:277-280.
47. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;19:1-9.
48. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
49. Grant AM, Avenell A, Campbell MK, et al (RECORD Trial Group). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365:1621-1628.
50. Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med. 2005;165:1618-1623.
51. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157:332-337.
52. Haug C, Müller F, Aukrust P, Frøland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169:889-893.
53. Range N, Changalucha J, Krarup H, Magnussen P, Andersen AB, Friis H. The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania. Br J Nutr. 2006;95:762-770.
54. Villamor E, Mugusi F, Urassa W, et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis. 2008;197:1499-1505.